Welcome to Shandong Sinobioway Biomedical Co., Ltd.
CN | EN

Home>News Center > Media Focus

In June 2015, the former Zibo Wanchang Technology Co., Ltd. merged with the unnamed biopharmaceutical company through a major asset restructuring. On October 19, 2015, the company's name was changed to "Shandong Unnamed Biopharmaceutical Co., Ltd.". With the approval of Shandong Commerce Department by Foreign Trade Corporation of Shandong Province on November 16, 2009 (now transformed into a domestic-funded enterprise) approved by Shandong Provincial Department of Commerce under No. 28 [2009] of Lu Commerce and Investment Bureau, Zibo Wanchang Science and Technology Development Co., Ltd. was renamed as Foreign-invested Enterprise Co., On April 22, 2011, approved by CSRC License [2011] No. 589 issued by the China Securities Regulatory Commission, the Company was approved to publicly issue 27.08 million new shares to the domestic public. On May 10, 2011, the Company actually issued 27.08 million ordinary shares of RMB, net proceeds of RMB 471,272,858.31 after deducting various issuance expenses, and the total share capital of the Company after the initial public offering was 108.28 million shares. The shares of the Company were listed on the SME Board of Shenzhen Stock Exchange on May 20, 2011 with the stock short name of "Wanchang Technology" with the stock code of 002581.
      On July 31, 2015, the Company issued shares and paid for cash to buy assets and related party transactions were approved by the China Securities Regulatory Commission (Approval Number: Zheng Jian Xu Ke [2015] No. 1853). The reorganization involved the underlying assets of 100% stake in the pharmaceutical Co., Ltd. was completed on August 20, 2015 delivery transfer. The new shares involved in the restructuring 378,207,586 shares of RMB ordinary shares (A shares) were completed and registered in China Securities Depository and Clearing Co., Ltd. Shenzhen Branch on September 15, 2015 and were listed on the Shenzhen Stock Exchange on September 24, 2015 Listed, the nature of shares of tradable shares. Upon the application of the Company and the approval of the Shenzhen Stock Exchange, the stock abbreviation of October 2015 was changed to "Unnamed Medicine". Upon completion of this transaction, Beida Bioengineering Group Co., Ltd. held approximately 26.38% of the shares of the Company and became the controlling shareholder of the Company.

[Back]